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IN INFLAMMATORY AIRWAY DISORDERS, such as asthma and chronic obstructive pulmonary disease (COPD), bacterial and viral infections are important factors contributing to exacerbation in respiratory diseases (28) . Pathogens interact with airway cells via Toll-like receptors (TLRs), a family of pattern-recognition receptors that recognize pathogen-associated molecular patterns. The airway smooth muscle (ASM) plays an important immunomodulatory function in chronic inflammatory airways disease, contributing to the perpetuation and amplification of airway inflammation (9) . Recent in vitro evidence demonstrates that ASM cells can also contribute via TLRs to the inflammatory milieu during exacerbations (reviewed in Ref.
17)
; therefore, investigation of the molecular mechanisms downstream of TLR signaling may identify new approaches to restrain infectious exacerbations in chronic airways disease.
Human ASM cells express mRNA for a number of TLRs (30) . Engagement of TLR2 and -4 by bacterial cell wall components such as lipopolysaccharide and lipopeptides and TLR3 by viral RNA has been shown to modulate ASM synthetic functions such as cytokine secretion (6 -7, 13, 19, 30) and cell adhesion molecule upregulation (20) . These studies support the involvement of ASM cells in the amplification of airway inflammatory responses during infectious exacerbations in asthma and COPD via augmented cytokine production.
To address this, we performed an in vitro study examining the hypothesis that infectious stimuli may potentiate ASM inflammatory responses and contribute to neutrophilic inflammation. Neutrophils play a pivotal role in host defense against pathogens, but when their accumulation is excessive, such as in bacterial exacerbations in asthma and COPD, airway damage can ensue (reviewed in Ref. 29) . TLR2 has been implicated as a key contributor in neutrophilic inflammation (29) ; importantly, the TLR2 receptor is functional on ASM cells (19, 30) and TLR2 ligation has been shown to induce ASM secretion of the neutrophil chemoattractant chemokine IL-8 (30) and IL-6 (7), a cytokine that promotes neutrophil survival (5) . Thus, in this study, we determine whether ligation of TLR2 by the synthetic bacterial lipoprotein Pam3CSK4 augments the expression of TNF␣-induced IL-6 and IL-8 in primary cultures of human ASM cells and potentiates neutrophil chemotaxis.
We also aim to uncover the cellular signaling pathways activated by TLR2 ligation in human ASM cells. TLRs recognize pathogens and initiate diverse responses through distinct cellular signaling pathways. Ligation of TLR2 commonly activates MyD88/TRAF6-dependent pathways to induce proinflammatory cytokine expression via MAPK-and NF-B-mediated gene expression (16) . However, cell and species differences are known to exist (15) , and the role of other transcription factors in TLR2-mediated gene expression, such as cAMP response element binding (CREB) protein, has recently emerged (18, 21) . To date, only a few studies have investigated TLR2 signaling in ASM cells. Lee et al. (19) reported that the MyD88/TRAF6-pathway is responsible for TLR2 signaling induced in human ASM cells by lipoteichoic acid, a component of Gram-positive bacteria cell wall. In ASM cells from the Brown Norway rat, Chiou and Lin (7) demonstrated that Pam3CSK4 induces cytokine secretion (including IL-6) and activates NF-B-mediated signaling. Further investigations in primary ASM cultures of human origin are warranted, as understanding and targeting these pathways may allow regulation of the excessive proinflammatory response during infectious exacerbation.
Herein we show that Pam3CSK4 robustly amplifies TNF␣-induced IL-6 and IL-8 expression in ASM cells and enhances neutrophil chemotaxis. We demonstrate that the effect of Pam3CSK4 occurs via phosphorylation of CREB protein at Ser 133 and CRE-mediated transcription, rather than via enhanced NF-B-or MAPK-mediated signaling. Our findings suggest that ligation of TLR2 may enhance airway smooth muscle inflammatory responses during infectious exacerbations of chronic airway diseases such as asthma and COPD.
MATERIALS AND METHODS
Cell culture. Human bronchi were obtained from patients undergoing surgical resection for carcinoma or lung transplant donors in accordance with procedures approved by the Sydney South West Area Health Service and the Human Research Ethics Committee of the University of Sydney. ASM cells were dissected, purified and cultured as previously described by Johnson et al. (14) . A minimum of three different ASM primary cell lines were used for each experiment.
Unless otherwise specified, all chemicals used in this study were purchased from Sigma-Aldrich (St. Louis, MO).
Real-time RT-PCR. Total RNA was extracted using the RNeasy mini kit (Qiagen, Doncaster, VIC, Australia) and reverse transcription performed by using the RevertAid first strand cDNA synthesis kit (Fermentas Life Sciences, Hanover, MD) as per the manufacturer's protocol. IL-6, IL-8, and TLR2 mRNA levels were measured using real-time RT-PCR on an ABI Prism 7500 (Applied Biosystems, Foster City, CA) with IL-6 (Hs00174131_m1), IL-8 (Hs00174103_m1), or TLR2 (Hs00610101_m1) TaqMan gene expression assays and the eukaryotic 18S rRNA endogenous control probe (Applied Biosystems) subjected to the following cycle parameters: 50°C for 2 min, 1 cycle; 95°C for 10 min, 1 cycle; 95°C for 15 s, 60°C for 1 min, 40 cycles.
ELISAs. Cell supernatants were collected and stored at Ϫ20°C for later analysis by ELISA or cytokine array. IL-6 and IL-8 ELISAs were performed according to the manufacturer's instructions (BD Biosciences Pharmingen, San Diego, CA NF-B translocation. Cytoplasmic and nuclear protein extraction was performed using NE-PER nuclear and cytosolic extraction kit according to the manufacturer's instructions (Thermo Fisher Scientific, Rockford, IL). p50 or p65 NF-B was quantified by Western blotting using rabbit polyclonal IgG antibodies [C-20 (p65) or H-119 (p50): Santa Cruz Biotechnology] compared with ␣-tubulin and lamin A/C (rabbit polyclonal IgG antibodies; Cell Signaling Technology) as loading controls for the cytosolic and nuclear fractions, respectively. Translocation of p65 NF-B to the nucleus was detected by immunofluorescence as previously published (27) , with the rabbit polyclonal antibody against NF-B p65 (C-20) detected by an Alexa488 conjugated donkey anti-rabbit IgG antibody (Invitrogen, Carlsbad, CA). Nuclei were visualized using DAPI (Molecular Probes, Eugene, OR).
Transfection. ASM cells were transiently transfected with either pIL-6-luc 651 or pIL-6-luc 158 as previously described (2, 11) . The full-length IL-6 promoter construct pIL-6-luc 651 is a pGL3 luciferase reporter vector (Promega, Madison, WI) incorporating a 651-bp fragment of the human IL-6 gene promoter containing transcription factor consensus binding elements for the glucocorticoid receptor, activator protein-1 (AP-1), CCAAT enhancer-binding protein-␤, NF-B, and CRE (kindly provided by Dr. Oliver Eickelberg, LudwigMaximilians-Universität and Helmholtz Zentrum, München, Germany; Ref. 10) . The pIL-6-luc 158 construct is a truncated version of the IL-6 promoter without the AP-1 and CREB elements (described in ref.
2 as pIL-6-luc 160). To exclude the involvement of the AP-1 element in Pam3CSK4-induced luciferase activity, parallel studies were performed using a pIL-6-luc 651 construct where the AP-1 site had been deleted (pIL-6-luc 651 ⌬AP-1: described in Refs. 2, 10). NF-B activity assays were performed with the NF-B reporter vector pNF-B-Luc, according to our previously published methods (12, 23) .
Neutrophil chemotaxis. Neutrophils were purified from anticoagulated venous blood of a healthy volunteer by discontinuous density gradient centrifugation with monopoly resolving medium (MP Biomedicals, Solon, OH; Ref. 31) . Neutrophil chemotaxis towards conditioned media from treated ASM cells was quantified microscopically using a 96-well microchemotaxis chamber (Neuroprobe, Gaithersburg, MD) as previously published (12) . Parallel studies were conducted by incubating conditioned media from treated ASM cells for 1 h with neutralizing antibody (2 g/ml) against human IL-8 (mouse monoclonal IgG 1) or isotype control (R&D Systems: Minneapolis, MN) before measurement of neutrophil chemotaxis.
Statistical analysis. Statistical analysis was performed using either the Student's unpaired t-test or two-way ANOVA followed by Bonferroni's posttest. P values Ͻ0.05 were sufficient to reject the null hypothesis for all analyses.
RESULTS

Pam3CSK4 augments TNF␣-induced IL-6 and IL-8 expression in ASM cells. Stimulation of ASM cells with Pam3CSK4
(1 g/ml) or TNF␣ (10 ng/ml) alone for 24 h significantly increased IL-6 and IL-8 protein secretion (Fig. 1, A and B) . Furthermore, Pam3CSK4 significantly augmented TNF␣-induced IL-6 and IL-8 protein secretion by ϳ3.7 Ϯ 0.8-and 2.6 Ϯ 0.4-fold, respectively (P Ͻ 0.05). This upregulation was also observed at the mRNA level where Pam3CSK4 significantly augmented TNF␣-induced IL-6 and IL-8 mRNA expression by 4.6 Ϯ 1.2-and 6.9 Ϯ 1.8-fold, respectively, as demonstrated in Fig. 1 , C and D (P Ͻ 0.05).
Pam3CSK4-mediated potentiation of ASM inflammatory responses is not due to enhanced TLR2 expression. TLR ligands induce the expression of their cognate receptors in ASM cells (30) . Thus we determined whether Pam3CSK4-mediated potentiation of ASM cell cytokine production occurs as a result of increased TLR2 expression. Stimulation of ASM cells with Pam3CSK4 or TNF␣ alone induced a time-dependent increase in TLR2 mRNA expression ( Fig. 2A) . However, when ASM cells were treated with Pam3CSK4 and TNF␣ in combination, there was no significant difference in the temporal kinetics of TLR2 mRNA expression in cells stimulated with TNF␣ alone compared with treatment with Pam3CSK4 ϩ TNF␣ ( Fig. 2A) . Moreover, TNF␣-induced protein was similarly unaffected by Pam3CSK4 pretreatment (Fig. 2B) , where densitometric analysis showed that Pam3CSK4 had no significant effect on TLR2 protein upregulation induced after 24-h stimulation with TNF␣ (Fig. 2C) .
Pam3CSK4-mediated potentiation of ASM inflammatory responses is not due to enhanced NF-b signaling.
Because TLR2 activation has been shown to lead to the activation of NF-B in cell types apart from ASM (16) , and in ASM cells of rat origin (7), we examined whether Pam3CSK4 activates NF-B signaling in ASM cells from humans. NF-B is usually held in an inactive state in association with inhibitory IB␣. Signals that induce NF-B activity cause the phosphorylation of IB␣, their dissociation, and subsequent degradation by the proteasome that allows NF-B proteins (p50 and p65 subunits) to enter the nucleus and induce gene expression. We examined the effect of Pam3CSK4 on TNF␣-induced IB␣ degradation and, as shown in Fig. 3A , TNF␣ stimulation of ASM cells caused a rapid degradation of IB␣ after only 10 min of treatment. Importantly, the levels of IB␣ were unchanged by Pam3CSK4 and there was no effect on TNF␣-induced IB␣ degradation when ASM cells were treated with Pam3CSK4 and TNF␣ in combination.
We then investigated the effects of Pam3CSK4 on TNF␣-induced NF-B nuclear translocation. As evident from Fig. 3B , the amount of NF-B in the nuclear fraction of the cell lysates was unchanged after treatment with Pam3CSK4 alone. While there was an expected increase in the amount of both p50 and p65 NF-B in the nuclear fraction after TNF␣ treatment, there was no augmentation when ASM cells were pretreated with Pam3CSK4. The lack of effect of Pam3CSK4 on TNF␣-induced NF-B nuclear translocation was further confirmed using immunofluorescence microscopy. As shown in Fig. 3C , after a 30-min stimulation with TNF␣, p65 NF-B was found in the nucleus of ASM cells. Pam3CSK4 alone did not induce translocation of p65 NF-B into the nucleus of ASM cells and had no additional effect on TNF␣-induced NF-B nuclear translocation.
Finally, we performed NF-B luciferase reporter assays and while we demonstrated that TNF␣ robustly enhances NF-B activity, in corroboration of our previous studies (12, 23) , there was no potentiation by Pam3CSK4 (Fig. 3D ). Taken together, Fig. 2 . Pam3CSK4-mediated potentiation of ASM inflammatory responses is not due to enhanced Toll-like receptor 2 (TLR2) expression. A: growtharrested ASM cells were pretreated with vehicle or Pam3CSK4 (1 g/ml) for 1 h, followed by treatment with vehicle or TNF␣ (10 ng/ml) for 0, 1, 2, 4, 8, and 24 h. TLR2 mRNA expression was quantified by real-time RT-PCR, and results are expressed as fold increase compared with vehicle-treated cells at 0 h. Statistical analysis was performed using two-way ANOVA and then Bonferroni's posttest: *significant effect of treatment on TLR2 mRNA expression, compared with vehicle-treated cells at the same time point (means Ϯ SE values from n ϭ 7 primary ASM cell lines; P Ͻ 0.05). B: to confirm that Pam3CSK4 had no effect on TNF␣-induced TLR2 protein upregulation, growth-arrested ASM cells were pretreated with vehicle or Pam3CSK4 (1 g/ml) for 1 h, followed by treatment with vehicle or TNF␣ (10 ng/ml) for 24 h. Cells were then lysed, and TLR2 was analyzed by Western blotting, compared with ␣-tubulin as a loading control. Representative Western blot (B) and densitometric analysis (C) show the lack of effect of Pam3CSK4 on TNF␣-induced TLR2 protein (results expressed as fold increase). Results represent n ϭ 3 primary ASM cell lines. these data suggest that Pam3CSK4-mediated potentiation of ASM inflammatory responses is not due to enhanced NF-B signaling.
Pam3CSK4 does not activate MAPKs, or enhance TNF␣-induced MAPK phosphorylation, but does activate CREB and induce CRE-mediated transcriptional regulation.
Because TLR2 activation had been shown to lead to the activation of MAPK-mediated signaling pathways (7, 16) , we now examined the effect of Pam3CSK4 alone, or in combination with TNF␣, on phosphorylation of the MAPK family members, ERK, p38 MAPK, and JNK, in human ASM cells. As demonstrated in Fig. 4A , we confirmed that TNF␣ induced activation of all MAPKs in a temporally distinct pattern, as previously described (24, 26) . Notably, Pam3CSK4 added alone did not activate MAPK nor augment TNF␣-induced MAPK signaling when ASM cells were treated with Pam3CSK4 and TNF␣ in combination (Fig. 4A) .
Activation of the transcription factor CREB by Pam3CSK4 has recently been shown to be responsible for regulation of TLR2-mediated responses (18) , and the role of CREB/CRE- Fig. 3 . Pam3CSK4-mediated potentiation of ASM inflammatory responses is not due to enhanced NF-B signaling. A: to examine the effects of Pam3CSK4 on TNF␣-induced IB␣ degradation, growth-arrested ASM cells were pretreated with vehicle or Pam3CSK4 (1 g/ ml) for 1 h, followed by treatment with vehicle or TNF␣ (10 ng/ml) for 0, 10, 30, and 60 min. Cells were then lysed, and IB␣ was analyzed by Western blotting, compared with ␣-tubulin as a loading control. B: to investigate the effects on p50/p65 NF-B nuclear translocation, growth-arrested ASM cells were pretreated with vehicle or Pam3CSK4 (1 g/ml) for 1 h, followed by treatment with vehicle or TNF␣ (10 ng/ml) for 30 min. Cytoplasmic and nuclear protein extracts were prepared and nuclear entry of NF-B p50/p65 quantified by Western blotting, compared with ␣-tubulin and lamin A/C as loading controls for the cytosolic and nuclear fractions, respectively. C: immunofluorescence microscopy was used to confirm p65 NF-B nuclear translocation in ASM cells treated as in B. NF-B translocation was determined using an antibody against NF-B p65, and nuclei were visualized with DAPI. Results represent n ϭ 3 primary ASM cell lines. D: ASM cells transiently transfected with a NF-B reporter vector, pNF-B-Luc, were growth arrested and then pretreated with vehicle or Pam3CSK4 (1 g/ml) for 1 h, followed by treatment with vehicle or TNF␣ (10 ng/ml) for 6 h. Data represent normalized luciferase activity, relative to vehicle-treated cells (expressed as fold difference). Statistical analysis was performed using the Student's unpaired t-test: *significant effect of treatment on NF-B activity (means Ϯ SE values from n ϭ 3 primary ASM cell lines; P Ͻ 0.05). mediated gene expression pathways upon TLR2 activation has emerged (21) . The treatment conditions used throughout this study use a 1-h period of pretreatment with Pam3CSK4 (1 g/ml) before stimulation with TNF␣ (10 ng/ml), compared with vehicle control. It is possible that Pam3CSK4 activates CREB phosphorylation at the end of the pretreatment period, i.e., before the addition of TNF␣. This was examined in Fig. 4 , B and C, where we addressed whether Pam3CSK4 activates CREB in ASM after a 60-min stimulation with Pam3CSK4. We found that the TLR2 ligand activated CREB at this time (1 g/ml) for 1 h, followed by treatment with vehicle or TNF␣ (10 ng/ml) for 0, 10, 30, and 60 min. Cells were then lysed, and phosphorylation of MAPKs was analyzed by Western blotting using phospho-specific antibodies, compared with total MAPK. B and C: to demonstrate the effect of Pam3CSK4 on CREB activation, growth-arrested cells were treated with either vehicle or Pam3CSK4 for 60 min, and then CREB phosphorylation was determined by Western blotting. Representative Western blot (B) and densitometric analysis (C) show Pam3CSK4-induced CREB phosphorylation at 60 min (results expressed as fold increase compared with vehicle-treated control). Statistical analysis was performed using the Student's unpaired t-test: *significant effect of Pam3CSK4 on CREB phosphorylation, compared with vehicle-treated cells (P Ͻ 0.05). Results are representative of n ϭ 3 primary ASM cell lines. D: graphical representation of the pIL-6-luc 651 and pIL-6-luc 158 constructs. E: ASM transfected with pIL-6-luc 651 or pIL-6-luc 158 were growth-arrested and then pretreated with vehicle or Pam3CSK4 (1 g/ml) for 1 h, followed by treatment with vehicle or TNF␣ (10 ng/ml) for 24 h. Data represent normalized luciferase activity, relative to vehicle-treated cells (expressed as fold difference). F: to exclude the involvement of the activator protein-1 (AP-1) binding element, Pam3CSK4-induced luciferase activity was compared in ASM cells transfected with pIL-6-luc 651 or pIL-6-luc 651 ⌬AP-1. Data represent normalized luciferase activity, relative to cells transfected with pIL-6-luc 651 (expressed as fold difference). Statistical analysis was performed using the Student's unpaired t-test: *significant effect of treatment on luciferase activity (compared with vehicle-treated cells); §significant effect of Pam3CSK4 on TNF␣-induced luciferase activity; ϱsignificant difference between luciferase activity in cells transfected with pIL-6-luc 158 compared with pIL-6-luc 651; NS, CRE truncation does not significantly alter the luciferase activity of the IL-6 promoter in Pam3CSK4 ϩ TNF␣-treated cells compared with TNF␣-treated cells (means Ϯ SE values from n ϭ 3 primary ASM cell lines; P Ͻ 0.05).
point. This is demonstrated by Western blotting in Fig. 4B , where there were greater levels of phospho-CREB (Ser 133 ) after treatment with Pam3CSK4 and in Fig. 4C where densitometric analysis revealed that Pam3CSK4 significantly increased CREB phosphorylation by 2.0 Ϯ 0.5-fold, compared with vehicle-treated cells (P Ͻ 0.05).
Moreover, as the 5=-promoter for IL-6 contains a CRE consensus sequence (2), we confirmed the role of CREB/CRE pathway by transient transfection of ASM cells with either the full-length IL-6 promoter (pIL-6-luc 651) or an IL-6 promoter construct where the CREB element had been removed (pIL-6-luc 158; represented graphically as Fig. 4D ). As shown in Fig.  4E , Pam3CSK4 or TNF␣ added individually to ASM cells significantly increased full-length IL-6 promoter activity by 2.5 Ϯ 0.6-or 2.5 Ϯ 0.3-fold, respectively, compared with vehicle-treated cells (P Ͻ 0.05). Importantly, IL-6 promoter activity in response to Pam3CSK4 was lost when the CREB element was removed. This is shown in Fig. 4E , where Pam3CSK4-induced luciferase activity in cells transfected with the pIL-6-luc 158 truncated promoter was reduced to a level that was not significantly different from vehicle-treated cells (1.1 Ϯ 0.2-fold). As the pIL-6-luc 158 construct is a truncated version of the IL-6 promoter missing both the AP-1 and CREB elements (Fig. 4D) , we performed parallel studies to exclude the involvement of AP-1. As shown in Fig. 4F , there was no significant difference in Pam3CSK4-induced luciferase activity using a pIL-6-luc 651 construct where the AP-1 site had been deleted, compared with the full-length IL-6 promoter. In accordance with our previous report (2) that TNF␣-induced IL-6 transcriptional regulation is NF-B-, not CRE-mediated, the extent of TNF␣-induced promoter activity was similar in cells transfected with the full-length or truncated construct. Finally, when added in combination, Pam3CSK4 significantly increased TNF␣-induced pIL-6-luc 651 luciferase activity (from 2.5 Ϯ 0.3-to 3.6 Ϯ 0.4-fold), and this activity was reduced when the CREB element was removed (1.6 Ϯ 0.2-fold; P Ͻ 0.05). Thus Pam3CSK4 and TNF␣ appear to act in concert to enhance ASM cytokine secretion via parallel transcriptional pathways.
Pam3CSK4 and TNF␣ enhance human neutrophil chemotaxis in vitro. Pam3CSK4 and TNF␣ alone or in combination act to augment the synthetic function of ASM and increase the levels of the potent neutrophil chemoattractant chemokine, IL-8, and the neutrophil prosurvival cytokine IL-6. In Fig. 5A , we show that human neutrophils undergo significantly more migration toward conditioned media from ASM cells treated with Pam3CSK4 (28.4 Ϯ 2.5 cells/high-power field) or TNF␣ (98.9 Ϯ 8.1 cells/high power field), compared with vehicletreated cells (9.7 Ϯ 1.9 cells/high power field; P Ͻ 0.05). Notably, chemotaxis of human neutrophils was significantly enhanced toward supernatants from ASM cells treated with Pam3CSK4 and TNF␣ in combination (171.1 Ϯ 8.0 cells/highpower field) (P Ͻ 0.05). In parallel studies, conditioned media from treated ASM cells were preincubated with neutralizing antibodies towards human IL-8 and compared with isotype control. As shown in Fig. 5B , there was significantly less neutrophil chemotaxis towards conditioned media from cells stimulated with Pam3CSK4, TNF␣, or both when IL-8 had been neutralized, demonstrating the potential role in neutrophil chemotaxis played by IL-8 secreted from ASM cells measured in vitro following TLR2 activation.
DISCUSSION
In this study, we showed that engagement of TLR2 by the synthetic bacterial lipopeptide Pam3CSK4 robustly upregulated TNF␣-induced IL-6 and IL-8 expression from ASM cells. Interestingly, the mechanism underlying the augmentation of TNF␣-induced cytokine production by Pam3CSK4 in ASM differs from other cell types, in that activation of NF-B-or MAPK-mediated pathways was not observed. Enhanced mRNA expression for TLR2 receptor was also not responsible. Instead, we showed that Pam3CSK4 induces CREB phosphorylation and CRE-mediated transcriptional regulation. We suggest that Pam3CSK4 and TNF␣ are acting in concert to enhance ASM cell inflammatory responses via parallel transcriptional pathways. Our findings indicate that ASM cells may be involved in the amplification of airway inflammatory responses during infectious exacerbations in asthma and COPD via augmented cytokine production. In support of this, we demonstrated that Pam3CSK4 potentiated ASM inflammatory responses and enhanced neutrophil chemotaxis measured in vitro.
Sukkar et al. (30) A: chemotaxis of human neutrophils toward conditioned media from growtharrested ASM cells pretreated with vehicle or Pam3CSK4 (1 g/ml) for 1 h, followed by treatment with vehicle or TNF␣ (10 ng/ml) for 24 h, was measured using microchemotaxis chambers. Results are expressed as cells per highpower (ϫ400) field. Statistical analysis was performed using the Student's unpaired t-test: *significant effect of treatment on neutrophil chemotaxis, compared with vehicle-treated cells; §significant effect of Pam3CSK4 on TNF␣-induced neutrophil chemotaxis (means Ϯ SE values from n ϭ 5 primary ASM cell lines). B: in parallel studies, supernatants from ASM cells treated as in A were incubated for 1 h with 2 g/ml human IL-8 neutralizing antibody (or isotype control) and neutrophil chemotaxis was measured. Statistical analysis was performed using the Student's unpaired t-test: *significant effect of treatment on neutrophil chemotaxis, compared with vehicle-treated cells; ϱsignificant inhibition by the IL-8 neutralizing antibody (means Ϯ SE values from n ϭ 5 primary ASM cell lines; P Ͻ 0.05).
the robust upregulation of cytokine secretion that occurred when ASM cells were stimulated with TLR2 ligand in combination with TNF␣ was that there was a corresponding increase in levels of the TLR2 receptor. To address this, we examined the temporal kinetics of TLR2 mRNA expression after treatment of ASM cells with Pam3CSK4 and TNF␣, alone or in combination. TLR2 expression after Pam3CSK4 treatment was significantly increased over time and TNF␣ induced a comparatively greater increase of TLR2 mRNA expression. This is in accord with Sukkar et al. (30) where Pam3CSK4 and TNF␣ added individually to ASM cells were shown to induce TLR2 receptor expression after 24 h. However, there was no significant difference between the temporal kinetics of TLR2 mRNA expression in cells stimulated with TNF␣ alone compared with treatment with Pam3CSK4 ϩ TNF␣. Moreover, TNF␣-induced TLR2 protein was not upregulated by Pam3CSK4.
In cell types apart from ASM, stimulation of the TLRs leads, through several activator proteins, to the activation of downstream signaling pathways such as NF-B and MAPKs and subsequently to increased production of proinflammatory cytokines, chemokines, and other inflammatory mediators (8, 16) . To date, there are limited studies elucidating the signaling pathways activated by TLR2 ligands in ASM cells (7, 19) . We (1, (3) (4) 23) and others (24) have established that TNF␣ leads to activation of NF-B and MAPKs, and this is corroborated in our current study. Somewhat unexpectedly, however, there was no effect of Pam3CSK4 alone on NF-B or MAPK activation nor was TNF␣-induced NF-B-or MAPK-signaling enhanced by pretreatment with Pam3CSK4. Our results in ASM are consistent with a recent study in primary cultures of human airway epithelial cells (32) where NF-B and MAPKs pathways do not account for the observed augmented inflammatory gene expression observed after treatment with the TLR2 ligand Pam3CSK4.
TLRs can trigger activation of other transcription factors apart from NF-B and contribution of CREB has been recently recognized (21) . This led us to examine CREB activation as a putative pathway leading to the enhanced secretion of proinflammatory cytokines from ASM cells mediated by TLR2 engagement. In cell types apart from ASM, Pam3CSK4-induced phosphorylation of CREB has been shown to be involved in regulation of TLR2-mediated immune response (18) . Importantly, both IL-6 and IL-8 are CREB-responsive genes as the 5=-promoter for IL-6 (2) and IL-8 (25) contain CRE consensus sequences and are induced by CREB-mediated pathways. To confirm the role of CREB/CRE pathway in Pam3CSK4-induced upregulation of TNF␣-mediated cytokine production from ASM cells, we performed transient transfection of ASM cells with either the full-length IL-6 promoter or an IL-6 promoter construct where the CREB element had been removed (2) . When added individually to ASM cells transfected with pIL-6-luc 651, Pam3CSK4 or TNF␣ enhanced full-length IL-6 promoter activity. Importantly, IL-6 promoter activity in response to Pam3CSK4 was lost using the pIL-6-luc 158-truncated promoter, suggesting that Pam3CSK4 transcriptional regulation may be CRE mediated. As pIL-6 158 lacks both CRE and AP-1 sites, we excluded the involvement of AP-1 by determining that Pam3CSK4-induced luciferase activity in full-length IL-6 promoter (pIL-6-luc 651) did not appear different from that in a pIL-6-luc 651 construct where the AP-1 site had been deleted. This suggests that effects observed are due to CRE truncation and not AP-1 site truncation. In contrast, TNF␣-induced promoter activity was equivalent in cells transfected with the full-length or truncated construct, confirming that TNF␣-induced IL-6 transcriptional regulation is NF-B mediated (2) . Together, Pam3CSK4 significantly increased TNF␣-induced IL-6 promoter activity, and our results are consistent with Pam3CSK4 and TNF␣ acting in concert to enhance ASM cytokine secretion via parallel transcriptional pathways.
ASM cells play an important immunomodulatory role, and in this study we provide further evidence to support a role for the involvement of ASM in the amplification of airway inflammatory responses during infectious exacerbations via augmented cytokine production. TLR receptors are expressed on ASM cells (22, 30) , and TLR engagement with synthetic ligands or bacterial products enhance TLR function and induce proinflammatory cytokine secretion from human ASM cells, including eotaxin and IL-8 (30). Our current report extends these studies to demonstrate that Pam3CSK4 also increases secretion of IL-6 and confirms the effect of TLR2 ligand on IL-8 secretion (30) . Secretion of IL-6 upon stimulation with Pam3CSK4 has been previously reported in ASM cells of rat origin (7) . We show a substantial potentiation of IL-6 and IL-8 expression when ASM cells are stimulated by inflammatory stimuli in the presence of a synthetic bacterial ligand for TLR2. The augmented effect on cytokine secretion by ASM may have important consequences in vivo, as was highlighted by the in vitro demonstration of enhanced neutrophil chemotaxis towards conditioned media from ASM cells that had been stimulated with Pam3CSK4 in combination TNF␣, as opposed to TNF␣ alone. These findings may have implications for our understanding of neutrophilic inflammation in asthma and COPD and bacterial exacerbations. We demonstrate that potentiation of ASM inflammatory responses by infectious stimuli was CREB-not NF-B mediated, thus targeting these pathways may allow regulation of the excessive proinflammatory response.
In summary, we have obtained greater insight into how respiratory infections in combination with inflammatory conditions in the airways are important factors that may contribute to disease exacerbations and identified key molecules regulating the ASM cells proinflammatory response.
